Skip to main content

Week in Review: Alphamab Oncology Plans $350 Million Hong Kong IPO

Deals and Financings • Alphamab Oncology, a company developing eight bispecifics for oncology, will complete an IPO before the end of the year on the Hong Kong Exchange that could raise up to $350 million; • Luye Pharma of Yantai paid $205 million to acquire Shandong Boan Biological, a biosimilars company with production capacity; previously. Luye in-licensed four biosimilars from Boan; • EOC Pharma, the oncology development arm of China in-licensing company Eddingpharm, raised $71 million in a Series C round for its pipeline of six novel oncology products; • Suzhou Ribo Life Science, a siRNA drug development company, completed a $29 million series C1 financing to support China development of 10 siRNA products, including six in-licensed from US-based Quark; • Beijing Hygea Medical closed a $28 million Series B funding to develop its minimally invasive cryogenic treatment for cancer; • Singapore's Aslan Pharma raised $12.8 million in a secondary offering of its NASDAQ listed ADSs; • ViGeneron GmbH of Munich closed a Series A round led by two China investors, WuXi AppTec and Sequoia Capital China, to develop viral vector-based gene therapy platforms and two lead ophthalmic gene therapies; Trials and Approvals • AstraZeneca and Merck/MSD were approved to sell their jointly marketed PARP inhibitor in China as a first-line maintenance treatment for BRCA-mutated ovarian cancer; • Suzhou Innovent dosed the first patient in a China Phase I trial of its novel immunotherapy, a LAG-3 candidate, in patients with advanced malignancies; • CASI Pharma announced China approval to start clinical trials of a CD19 CAR-T treatment in leukemia and lymphoma patients; • Innovative Cellular Therapeutics, a Shanghai-US CAR-T company, reported the US FDA approved its IND for a next gen CD19-targeting CAR-T cell therapy; • Bio-Thera of Guangzhou was approved to start a China Phase I trial that compares its Stelara® biosimilar to the original for immune disorders; Government and Regulatory • China's National Healthcare Security Administration added 70 drugs to the list of drugs eligible for insurance reimbursement after biopharmas agreed to price cuts that averaged 61%. Stock Symbols: (HK: 2186) (NSDQ: ASLN; TPEx: 6497) (NYSE: AZN) (NYSE: MRK) (HK: 01801) (NSDQ: CASI) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.